Outcomes of Patients on Dual-Boosted PI Regimens: Experience of the Swiss HIV Cohort Study

Abstract

Dual-boosted protease inhibitors (DBPI) are an option for salvage therapy for HIV-1 resistant patients. Patients receiving a DBPI in the Swiss HIV Cohort Study between January1996 and March 2007 were studied. Outcomes of interest were viral suppression at 24 weeks. 295 patients (72.5%) were on DBPI for over 6 months. The median duration was 2.2 years. Of 287 patients who had HIV-RNA >400 copies/ml at the start of the regimen, 184 (64.1%) were ever suppressed while on DBPI and 156 (54.4%) were suppressed within 24 weeks. The median time to suppression was 101 days (95% confidence interval 90-125 days). The median number of past regimens was 6 (IQR, 3-8). The main reasons for discontinuing the regimen were patient's wish (48.3%), treatment failure (22.5%), and toxicity (15.8%). Acquisition of HIV through intravenous drug use and the use of lopinavir in combination with saquinavir or atazanavir were associated with an increased likelihood of suppression within 6 months. Patients on DBPI are heavily treatment experienced. Viral suppression within 6 months was achieved in more than half of the patients. There may be a place for DBPI regimens in settings where more expensive alternates are not available.

Epidemiological and Immunological Characteristics at the Time of HIV Diagnosis for HIV/AIDS Cohort Registrants Representative of HIV-Infected Populations in Korea

“…The results of the HIV/AIDS cohort studies were applied to national programs for HIV prevention as well as to diagnostic and treatment guidelines for HIV-infected individuals, and the development of therapeutic drugs, thereby extending the survival of infected individuals and preventing the transmission of HIV infection [15,16]. In Europe, the multinational cohort, Concerted Action on SeroConversion to AIDS and Death in Europe (1997), in which 12 countries participated, was established for individuals whose HIV infection time can be predicted [17].…”

HIV-Antiretroviral Therapy Induced Liver, Gastrointestinal, and Pancreatic Injury

“…The drugs responsible for the observed ADRs are not specified [94]. GI toxicity was also reported in relation to didanosine [34].…”

“…GI symptoms were associated with treatment modifications in patients receiving treatment with dual-boosted PIs [ 94 ]. The drugs responsible for the observed ADRs are not specified [ 94 ]. GI toxicity was also reported in relation to didanosine [ 34 ].…”